Clinical Trials Logo

Ovarian Hyperstimulation clinical trials

View clinical trials related to Ovarian Hyperstimulation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04175990 Completed - IVF Clinical Trials

IVF Outcome Following Progestogen Ovarian Stimulation

Start date: May 10, 2018
Phase: Phase 1
Study type: Interventional

The new strategy is by using the progestogen to block the luteinizing hormone(LH) surge either endogenous during luteal phase stimulation, or exogenous in the follicular phase i.e progestin primed ovarian stimulation (PPOS). The goal of PPOS is to develop a single dominant follicle. Various types of oral Progestin had been studied before including Medroxyprogesterone Acetate (MPA) and Utrogestan with different dosage. A different study by Wang et al conducted by using MPA to patients with PCOS. The use of MPA is contraindicated in human pregnancy whereas Dydrogesterone had been extensively used worldwide for the treatment of threatened miscarriage as well as luteal support in infertility setting. Previous protocol on PPOS showed inconclusive results. Therefore in this study, Dydrogesterone was used as the Progestin Primed Ovarian hyperstimulation to explore its effect on PCOS women IVF outcome.

NCT ID: NCT04002141 Active, not recruiting - Endometriosis Clinical Trials

Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

APPOSE
Start date: September 17, 2019
Phase: Phase 2
Study type: Interventional

Randomized double blinded placebo-controlled trial to evaluate the impact of ovarian hyperstimulation on endometriosis-related symptoms and to evaluate the impact of letrozole use during ovarian hyperstimulation with respect to endometriosis-related symptoms, embryo/egg quality and quantity, and pregnancy rates.

NCT ID: NCT03473613 Completed - Clinical trials for Ovarian Hyperstimulation

Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

Start date: October 1, 2014
Phase: Phase 3
Study type: Interventional

Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention

NCT ID: NCT02975713 Terminated - Clinical trials for Ovarian Hyperstimulation

Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF

Start date: November 2, 2017
Phase: N/A
Study type: Observational

To evaluate the influence of circadian rhythm on progesterone levels during follicular phase of natural cycle and during follicular phase of controlled ovarian stimulation during IVF.

NCT ID: NCT02715336 Recruiting - Pregnancy Clinical Trials

Efficacy and Safety of Medication Used to Stimulate Ovulation

Start date: October 2015
Phase: Phase 4
Study type: Interventional

Individuals undergoing In Vitro Fertilization must undergo controlled ovarian hyperstimulation (COH) to produce enough quality eggs for fertility treatment. Ovarian follicular responsiveness to COH with gonadotropins is extremely variable between patients and even from cycle to cycle for the same patient. Achieving an ideal follicular response is critical to the success of assisted reproduction treatment (ART). Patients have been classified as 'poor', 'normal' or 'high' responders, which dictate the amount of gonadotropins that they receive. It is still important to develop treatments with high efficacy, lower multiple birth rates, and a lower complication rate for each of these groups. In an era of evidence-based medicine and with special emphasis on reducing IVF risks (mainly OHSS and pregnancies with multiples), it is very important to find optimal and safe ovulation induction and triggering regimens for each patient population. The use of GnRH agonist (GnRHa) triggering among high responders in order to reduce or eliminate OHSS is an example of an important breakthrough in the clinical management of IVF patients. Although GnRHa triggering was shown to be as effective as human chorionic gonadotropin (hCG) at inducing oocyte maturation more than 20 years ago, its use to trigger ovulation was not possible until the introduction of GnRH antagonists for pituitary suppression. Another prominent trend in ART in recent years has been the introduction of dual triggering, which involves a combination of GnRHa plus hCG for triggering. This regimen creates simultaneous lutenizing hormone (LH) and follicle stimulating hormone (FSH) surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, which stimulates the corpus luteum to excrete sufficient hormonal endometrial support. Since its introduction, dual triggering has been gaining popularity due to outstanding results in retrospective studies among both normal and high responders. Moreover, in spite of the encouraging retrospective reports, prospective randomized controlled trials (RCT) on dual triggering have not been reported to date. The aim of the current proposed study is to compare the efficacy of dual triggering and conventional triggering among the three IVF populations (high, normal and poor responders).

NCT ID: NCT02416596 Not yet recruiting - Infertility Clinical Trials

Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility

Start date: January 2016
Phase: N/A
Study type: Interventional

The aim of the present study is to evaluate the impact of hysteroscopy prior to starting the IVF (in vitro fertilisation) cycle on treatment outcome in women with unexplained primary infertility.